Skip to main content
Premium Trial:

Request an Annual Quote

Exiqon Licenses LNA to Phoenix BioTechnologies

NEW YORK, May 20 - Exiqon has non-exclusively licensed its Locked Nucleic Acids technology to Phoenix BioTechnologies, of Huntsville, Ala.


Under the agreement, Phoenix BioTechnologies will acquires the "recipe" for making LNA, and has the has the rights to manufacture and sell LNA oligonucleotides to the research market. The companies did not disclose the financial terms of the agreement.


LNA is LNA is a proprietary nucleic acid analog, which is incorporated in synthetic DNA oligos to enhance sensitivity in genomics products.


Exiqon, of Copenhagen, has also licensed this technology to DNAPrint of Sarasota, and Eurogentec of Sart-Tilman, Belgium.


The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.